• Sonia J Konsek-Komorowska, Mariola Pęczkowska, Agnieszka D Kolasińska-Ćwikła, Marek Konka, Eryk Chrapowicki, and Jarosław B Ćwikła.
• Department of Cardiology and Internal Medicine, School of Medicine, University of Warmia and Mazury, 10-082 Olsztyn, Poland. Electronic address: sonia.konsek@interia.pl.
• Med Clin (Barc). 2022 Jul 22; 159 (2): 85-89.

IntroductionProgression of carcinoid syndrome (CS) to carcinoid heart disease (CHD) is difficult to predict. This retrospective analysis evaluates the use of chromogranin A (CgA), a biomarker widely used in the diagnosis of neuroendocrine tumours (NET), in monitoring CS and disease progression.Patients And Methods108 patients with confirmed CS, selected from a group of 351 patients with neuroendocrine neoplasms of the small intestine (SI-NENs), including NETG1 well 40% and NETG2 60% moderately differentiated NET. CgA concentration was measured during initial diagnosis and clinical follow up in 84 patients, 27 of them subsequently developed CHD. The patient's overall survival (OS) was evaluated using the Kaplan-Meier method.ResultsPatients with CHD, were found to have significantly shorter OS than patients with CS but without CHD (67.22 vs. 73.03 months). Univariate and multivariate analyses revealed that initial high concentration of CgA and/or increased concentration of CgA is significantly associated with decreased median OS in patients with CS (p<0.05).ConclusionCgA has potential as a clinically useful biomarker in reporting disease status and predicting outcome in patients with CS and with CHD.Copyright © 2021 Elsevier España, S.L.U. All rights reserved.

28 keywords...

hide…